[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UY37205A - Inhibidores de bromodominios - Google Patents

Inhibidores de bromodominios

Info

Publication number
UY37205A
UY37205A UY0001037205A UY37205A UY37205A UY 37205 A UY37205 A UY 37205A UY 0001037205 A UY0001037205 A UY 0001037205A UY 37205 A UY37205 A UY 37205A UY 37205 A UY37205 A UY 37205A
Authority
UY
Uruguay
Prior art keywords
bromodominium
inhibitors
formula
compounds
diseases
Prior art date
Application number
UY0001037205A
Other languages
English (en)
Inventor
Dachun Liu
D Fidanze Steven
A Hasvold Lisa
F Mcdaniel Keith
John PRATT
Michael Schrimpf
Le Wang
Bing Li
S Sheppard George
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of UY37205A publication Critical patent/UY37205A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La presente invención provee compuestos de fórmula (I)en donde R1, R2, R3, R4, R6, X1, y X2 tienen cualquiera de los valores que se definen en la memoria descriptiva, y sales farmacéuticamente aceptables de los mismos, que son útiles como agentes para el tratamiento de enfermedades y condiciones, incluyendo enfermedades inflamatorias, cáncer, y SIDA. También se proveen composiciones farmacéuticas que comprenden los compuestos de fórmula (I).
UY0001037205A 2016-04-15 2017-04-18 Inhibidores de bromodominios UY37205A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2016079362 2016-04-15

Publications (1)

Publication Number Publication Date
UY37205A true UY37205A (es) 2017-11-30

Family

ID=60042835

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037205A UY37205A (es) 2016-04-15 2017-04-18 Inhibidores de bromodominios

Country Status (39)

Country Link
US (4) US10633379B2 (es)
EP (2) EP3693369A3 (es)
JP (2) JP6978424B2 (es)
KR (1) KR102250415B1 (es)
CN (1) CN109071534B (es)
AR (1) AR108207A1 (es)
AU (2) AU2017251537B2 (es)
BR (1) BR112018071216A2 (es)
CA (1) CA3018802A1 (es)
CL (1) CL2018002924A1 (es)
CO (1) CO2018011064A2 (es)
CR (1) CR20180541A (es)
CY (1) CY1123025T1 (es)
DK (1) DK3442972T3 (es)
DO (1) DOP2018000227A (es)
EC (1) ECSP18083519A (es)
ES (1) ES2793239T3 (es)
HR (1) HRP20200728T1 (es)
HU (1) HUE050217T2 (es)
IL (1) IL261586B (es)
LT (1) LT3442972T (es)
MA (2) MA44674B1 (es)
MD (1) MD3442972T2 (es)
ME (1) ME03759B (es)
MX (1) MX2018012541A (es)
MY (1) MY190795A (es)
PE (1) PE20190472A1 (es)
PH (1) PH12018501920B1 (es)
PL (1) PL3442972T3 (es)
PT (1) PT3442972T (es)
RS (1) RS60302B1 (es)
RU (1) RU2741808C2 (es)
SG (1) SG11201808003RA (es)
SI (1) SI3442972T1 (es)
SM (1) SMT202000312T1 (es)
TW (3) TWI764237B (es)
UA (1) UA124764C2 (es)
UY (1) UY37205A (es)
WO (1) WO2017177955A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018071216A2 (pt) * 2016-04-15 2019-02-05 Abbvie Inc inibidores de bromodomínios
JP2019534264A (ja) * 2016-10-14 2019-11-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
US11672800B2 (en) 2017-04-21 2023-06-13 Epizyme, Inc. Combination therapies with EHMT2 inhibitors
EP3828183A4 (en) * 2018-07-25 2022-03-09 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. SULFOXIMINE COMPOUND AS BROMO-DOMAIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
CN110776508B (zh) * 2018-07-27 2021-07-16 海创药业股份有限公司 一种brd4抑制剂及其制备方法和用途
WO2020063976A1 (zh) * 2018-09-29 2020-04-02 如东凌达生物医药科技有限公司 一类稠杂环联芳基苄醇类化合物、制备方法和用途
EP3873474A4 (en) 2018-10-30 2022-07-13 Nuvation Bio Inc. HETEROCYCLIC COMPOUNDS USED AS BET INHIBITORS
CN111704610B (zh) * 2019-03-17 2022-03-22 上海凌达生物医药有限公司 一类吡咯酰胺并吡啶酮类化合物、制备方法和用途
GB201905721D0 (en) * 2019-04-24 2019-06-05 Univ Dundee Compounds
WO2020232214A1 (en) * 2019-05-14 2020-11-19 Abbvie Inc. Treating acute myeloid leukemia (aml) with mivebresib, a bromodomain inhibitor
CN114286818B (zh) 2019-07-02 2024-09-20 诺维逊生物股份有限公司 作为bet抑制剂的杂环化合物
KR20220047290A (ko) * 2019-07-30 2022-04-15 엑스래드 테라퓨틱스, 인크. 항종양 요법에 사용하기 위한 이중 atm 및 dna-pk 억제제
CN112625036A (zh) * 2019-10-08 2021-04-09 上海海和药物研究开发股份有限公司 一类具有brd4抑制活性的化合物、其制备方法及用途
WO2021233371A1 (zh) * 2020-05-21 2021-11-25 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
GB202016977D0 (en) 2020-10-26 2020-12-09 In4Derm Ltd Compounds
WO2022116968A1 (zh) 2020-12-01 2022-06-09 成都苑东生物制药股份有限公司 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
CN115551861B (zh) * 2021-04-30 2024-05-28 成都硕德药业有限公司 一种新型brd4溴结构域protac蛋白降解剂、其制备方法及医药用途
US20240308998A1 (en) 2021-06-29 2024-09-19 Tay Therapeutics Limited Pyrrolopyridone derivatives useful in the treatment of cancer
CN115611890B (zh) * 2021-07-15 2024-05-31 成都硕德药业有限公司 一种新型噻吩类bet溴结构域抑制剂、其制备方法及医药用途
WO2025006827A1 (en) 2023-06-30 2025-01-02 Genzyme Corporation Substituted cyclic compounds and methods of treating phenylketonuria and other amino acidurias

Family Cites Families (174)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1507957A (en) 1975-03-25 1978-04-19 Byk Gulden Lomberg Chem Fab Nitrofuryl-pyrazole derivatives methods for producing them and medicaments comprising them
US4072746A (en) 1975-10-14 1978-02-07 Sterling Drug Inc. 3-Amino-5-(pyridinyl)-2(1H)-pyridinones
US4004012A (en) 1975-10-14 1977-01-18 Sterling Drug Inc. 3-Cyano-5-(pyridinyl)-2(1H)-pyridinones
DE2845456A1 (de) 1978-10-19 1980-08-14 Merck Patent Gmbh 6-arylpyridazin-3-one und verfahren zu ihrer herstellung
US4298609A (en) 1979-08-30 1981-11-03 Sterling Drug Inc. 4,5-Dihydro-6-(4-pyridinyl)-3-pyridazinol and salts, their preparation and use as blood pressure lowering agents
FR2478640A1 (fr) 1980-03-24 1981-09-25 Sanofi Sa Nouvelles thieno (2,3-d) pyridazinones-4 et thieno (2,3-d) pyridazinones-7, leur procede de preparation et leur therapeutique
US4304776A (en) 1980-04-28 1981-12-08 Sterling Drug Inc. 4-Substituted-6-(pyridinyl)-3(2h)-pyridazinones and their use as intermediates and cardiotonics
US4338446A (en) 1980-04-28 1982-07-06 Sterling Drug Inc. Di-(lower-alkyl)hydroxy-[2-oxo-2-(pyridinyl)ethyl]-propanedioates
US4337253A (en) 1980-04-28 1982-06-29 Sterling Drug Inc. 4,5-Dihydro-2-methyl-6-(4-pyridinyl)-3(2H)-pyridazinone and its use as a cardiotonic
US4346221A (en) 1980-04-28 1982-08-24 Sterling Drug Inc. Preparation of 4-amino-6-(pyridinyl)-3(2H)-pyridazinones from 6-(pyridinyl)-3(2H)-pyridazinones
US4305943A (en) 1980-04-28 1981-12-15 Sterling Drug Inc. 4-Amino-6-(pyridinyl)-3(2H)-pyridazinones and their use as cardiotonics
US4486431A (en) 1981-01-14 1984-12-04 Sterling Drug Inc. Cardiotonic use of 4,5-dihydro-6-(4-pyridinyl)-3(2H)-pyridazinones
US4559352A (en) 1981-03-30 1985-12-17 Sterling Drug Inc. 1,2-Dihydro-2-oxo-5-(hydroxy-and/or amino-phenyl)-nicotinonitriles and cardiotonic use thereof
US4404203A (en) 1981-05-14 1983-09-13 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4397854A (en) 1981-05-14 1983-08-09 Warner-Lambert Company Substituted 6-phenyl-3(2H)-pyridazinones useful as cardiotonic agents
US4515797A (en) 1981-09-08 1985-05-07 Sterling Drug Inc. 3-Amino-5-(hydroxy- and/or aminophenyl)-6-(lower-alkyl)-2(1H)-pyridinones and cardiotonic use thereof
US4465686A (en) 1981-09-08 1984-08-14 Sterling Drug Inc. 5-(Hydroxy- and/or amino-phenyl)-6-(lower-alkyl)-2-(1H)-pyridinones, their cardiotonic use and preparation
US4353905A (en) 1981-09-17 1982-10-12 Warner-Lambert Company Substituted 4,5-dihydro-6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones and 6-[4-(1H-imidazol-1-yl)phenyl]-3(2H)-pyridazinones
US4599423A (en) 1982-04-26 1986-07-08 Sterling Drug Inc. Preparation of 5-(hydroxy- and/or aminophenyl-6-lower-alkyl)-2(1H)-pyridinones
US4734415A (en) 1982-08-13 1988-03-29 Warner-Lambert Company Substituted 4,5-dihydro-6-(substituted)-phenyl-3(2H)-pyridazinones and 6-(substituted) phenyl-3(2H)-pyridazinones
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
DE3321012A1 (de) 1983-06-10 1984-12-13 A. Nattermann & Cie GmbH, 5000 Köln Substituierte 4,5-dihydro-6-(thien-2-yl)-3(2h)-pyridazinone und 6-(thien-2-yl)-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung
US4666902A (en) 1983-06-20 1987-05-19 Cassella Aktiengesellschaft Tetrahydropyridazinone derivatives, processes for their preparation and their use
GB8323553D0 (en) 1983-09-02 1983-10-05 Smith Kline French Lab Pharmaceutical compositions
US4816454A (en) 1984-09-21 1989-03-28 Cassella Aktiengesellschaft 4,5-dihydro-3(2H)-pyridazinones and their pharmacological use
US5192563A (en) 1986-10-22 1993-03-09 Wm. Wrigley, Jr. Company Strongly mint-flavored chewing gums with reduced bitterness and harshness
US5217735A (en) 1986-10-22 1993-06-08 Wm. Wrigley Jr. Company Method of making chewing gum with delayed release ingredients
US4863745A (en) 1986-10-22 1989-09-05 Wm. Wrigley Jr. Company Chewing gum containing zein coated high-potency sweetener and method
US5112625A (en) 1989-02-15 1992-05-12 Wm. Wrigley Jr. Company Aqueous zein coated sweeteners and other ingredients for chewing gum
US5221543A (en) 1986-10-22 1993-06-22 Firma Wilhelm Fette Gmbh Method of making a fast release stabilized aspartame ingredient for chewing gum
US4908371A (en) 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
US4919941A (en) 1987-12-18 1990-04-24 Wm. Wrigley Jr. Company Chewing gum containing delayed release protein sweetener and method
DE4134467A1 (de) 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JP3120857B2 (ja) 1990-02-19 2000-12-25 中外製薬株式会社 新規な縮合複素環化合物とこれを用いた抗喘息剤
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE69131268T2 (de) 1990-09-21 1999-12-30 Rohm And Haas Co., Philadelphia Dihydropyridazinone und Pyridazinone als Fungizide
CA2069877A1 (en) 1990-10-02 1992-04-03 Michio Nakanishi Ethynylphenyl derivative substituted by pyridazinone and medicament for circulatory disease containing the same as an effective ingredient
DE4127404A1 (de) 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
CN1038249C (zh) 1991-08-28 1998-05-06 罗姆和哈斯公司 含有二氢哒嗪酮及其相关化合物的杀菌组合物
US5716954A (en) 1991-10-09 1998-02-10 Syntex U.S.A. Inc. Benzopyridazinone and pyridopyridazinone compounds
ZA927755B (en) 1991-10-09 1994-04-08 Syntex Inc Pyrido pyridazinone and pyridazinthione compounds
DE4237656A1 (de) 1992-06-13 1993-12-16 Merck Patent Gmbh Benzimidazolderivate
CA2147504A1 (en) 1992-11-02 1994-05-11 Prasun K. Chakravarty Substituted phthalazinones as neurotensin antagonists
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9314412D0 (en) 1993-07-13 1993-08-25 Rhone Poulenc Agriculture New compositions of matter
EP0634404A1 (en) 1993-07-13 1995-01-18 Rhone Poulenc Agriculture Ltd. Phtalazin derivatives and their use as pesticides
TW263498B (es) 1993-11-10 1995-11-21 Takeda Pharm Industry Co Ltd
JP3247540B2 (ja) 1994-05-12 2002-01-15 株式会社日立製作所 パケット化通信装置および切替え装置
US5466697A (en) 1994-07-13 1995-11-14 Syntex (U.S.A.) Inc. 8-phenyl-1,6-naphthyridin-5-ones
AU691673B2 (en) 1994-11-14 1998-05-21 Dow Agrosciences Llc Pyridazinones and their use as fungicides
JPH08337583A (ja) 1995-04-13 1996-12-24 Takeda Chem Ind Ltd 複素環化合物およびその製造法
US5635494A (en) 1995-04-21 1997-06-03 Rohm And Haas Company Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides
WO1997001551A1 (en) 1995-06-26 1997-01-16 Fujisawa Pharmaceutical Co., Ltd. Pyrazole compounds and pharmaceutical compositions
IL118631A (en) 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
AU723064B2 (en) 1995-08-25 2000-08-17 Dow Agrosciences Llc Compositions having synergistic fungitoxic effects
DE69717160T2 (de) 1996-09-13 2003-05-08 Mitsubishi Pharma Corp., Osaka Thienotriazolodiazepinverbindungen und ihre medizinischen anwendungen
US5855654A (en) 1997-01-30 1999-01-05 Rohm And Haas Company Pyridazinones as marine antifouling agents
EE9900435A (et) 1997-04-01 2000-04-17 Astra Pharmaceuticals Limited Püridiini uued derivaadid ja neid sisaldavad ravimkoostised
US6245804B1 (en) 1997-05-30 2001-06-12 Schering Aktiengesellschaft Nonsteroidal gestagens
US6307047B1 (en) 1997-08-22 2001-10-23 Abbott Laboratories Prostaglandin endoperoxide H synthase biosynthesis inhibitors
NZ504045A (en) 1997-11-19 2001-06-29 Kowa Co Pyridazine derivatives with inhibitory action against interleukin-1-beta production
JP2001525413A (ja) 1997-12-05 2001-12-11 アストラゼネカ ユーケイ リミテッド 新規化合物
EP0934933A1 (en) 1998-02-06 1999-08-11 Byk Gulden Lomberg Chemische Fabrik GmbH Phthalazinones
TWI241295B (en) 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP3910365B2 (ja) 1998-07-16 2007-04-25 塩野義製薬株式会社 抗腫瘍活性を有するピリミジン誘導体
US6271380B1 (en) 1998-12-30 2001-08-07 Dupont Pharmaceuticals Company 1H-imidazo[4,5-d]pyridazin-7-ones, 3H-imidazo-[4,5-c]pyridin-4-ones and corresponding thiones as corticotropin releasing factor (CRF) receptor ligands
CN1297916A (zh) 1999-11-26 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人含溴基结构域的蛋白95和编码这种多肽的多核苷酸
DE10010423A1 (de) 2000-03-03 2001-09-06 Bayer Ag Substituierte 2,5-Dimethyldihydropyridazinone und ihre Verwendung
CN1315397A (zh) 2000-03-28 2001-10-03 上海博德基因开发有限公司 一种新的多肽——人溴基结构域10和编码这种多肽的多核苷酸
AU5696800A (en) 2000-07-04 2002-01-14 Robert John Eyre Harvesting machine
US20030114448A1 (en) 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
JP2003313169A (ja) 2002-04-19 2003-11-06 Otsuka Chemical Holdings Co Ltd ４，４−ジフルオロ−３−ブテニル化合物及び農園芸用殺虫・殺ダニ剤
ES2195785B1 (es) 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
WO2004014892A1 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Monocyclic derivatives as matrix metalloproteinase inhibitors
WO2004014384A2 (en) 2002-08-13 2004-02-19 Warner-Lambert Company Llc Cyclic compounds containing zinc binding groups as matrix metalloproteinase inhibitors
JP4735261B2 (ja) 2003-06-27 2011-07-27 Ｍｓｄ株式会社 ヘテロアリールオキシ含窒素飽和ヘテロ環誘導体
WO2005000818A1 (en) 2003-06-27 2005-01-06 Warner-Lambert Company Llc 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors
DE602004025258D1 (de) 2003-08-06 2010-03-11 Vertex Pharma Aminotriazol-verbindungen als proteinkinase-hemmer
AR045595A1 (es) * 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
EP1677599A4 (en) 2003-10-20 2008-10-22 Merck & Co Inc DIONE HYDROXY PYRIDOPYRROLOPYRAZINE COMPOUNDS USEFUL AS INHIBITORS OF HIV INTEGRASE
SG115845A1 (en) 2004-03-31 2005-10-28 Univ Singapore Modulation of trip-br function and method of treating proliferative disorders
ATE533765T1 (de) * 2004-09-03 2011-12-15 Yuhan Corp Pyrroloä2,3-cüpyridinderivate und verfahren für deren herstellung
GB0420970D0 (en) 2004-09-21 2004-10-20 Smithkline Beecham Corp Novel triazoloquinoline compounds
WO2006038734A1 (en) 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006060127A2 (en) 2004-11-30 2006-06-08 Artesian Therapeutics, Inc. COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE
CA2588867A1 (en) 2004-12-01 2006-06-08 Banyu Pharmaceutical Co., Ltd. Substituted pyridone derivative
ATE537170T1 (de) 2005-03-14 2011-12-15 Merck Sharp & Dohme Cgrp-rezeptorantagonisten
US20060276496A1 (en) 2005-03-17 2006-12-07 Boehringer Ingelheim Pharmaceuticals, Inc. Anti-Cytokine Heterocyclic Compounds
JPWO2006112331A1 (ja) 2005-04-13 2008-12-11 大日本住友製薬株式会社 新規縮合ピロール誘導体
US8044042B2 (en) 2005-05-30 2011-10-25 Mitsubishi Tanabe Pharma Corporation Thienotriazolodiazepine compound and medicinal use thereof
WO2007008145A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
WO2007008144A1 (en) 2005-07-08 2007-01-18 Astrazeneca Ab Heterocyclic sulfonamide derivatives as inhibitors of factor xa
EP1953148B1 (en) 2005-10-28 2012-02-29 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
JP5335675B2 (ja) 2006-07-25 2013-11-06 セファロン、インク． ピリジジノン誘導体
US20080119457A1 (en) 2006-08-24 2008-05-22 Serenex, Inc. Benzene, Pyridine, and Pyridazine Derivatives
US7838523B2 (en) 2006-09-11 2010-11-23 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
EP2441768A1 (en) 2006-11-13 2012-04-18 Eli Lilly & Co. Thienopyrimidinones for treatment of inflammatory disorders and cancers
JP5639762B2 (ja) 2006-12-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド ウイルス阻害剤
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
US20080312307A1 (en) 2007-05-25 2008-12-18 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
CL2008002793A1 (es) 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
EP2426109B1 (en) 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
WO2009054790A1 (en) 2007-10-26 2009-04-30 Astrazeneca Ab Amide linked heteroaromatic derivatives as modulators of mglur5
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
EP2239264A4 (en) 2007-12-28 2012-01-11 Mitsubishi Tanabe Pharma Corp ANTITUMOR AGENT
US20100137320A1 (en) 2008-02-29 2010-06-03 Schering Corporation Gamma secretase modulators
EP2291370B1 (en) 2008-05-01 2013-11-27 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
TW200946520A (en) 2008-05-01 2009-11-16 Vitae Pharmaceuticals Inc Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
WO2009134384A1 (en) 2008-05-01 2009-11-05 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
EP2328586A2 (en) 2008-05-20 2011-06-08 Cephalon, Inc. Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands
KR20110050459A (ko) 2008-07-25 2011-05-13 비타이 파마슈티컬즈, 인코포레이티드 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제
WO2010127237A2 (en) 2009-04-30 2010-11-04 Boehringer Ingelheim International Gmbh Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1
CN102177152A (zh) 2008-08-11 2011-09-07 哈佛大学校长及研究员协会 用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
MX2011005284A (es) 2008-11-20 2011-06-17 Merck Sharp & Dohme Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1.
EP2196465A1 (en) 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
GB0919426D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
EP2496945B1 (en) 2009-11-05 2015-04-01 GlaxoSmithKline LLC Novel process
GB0919434D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EA020390B1 (ru) 2009-11-05 2014-10-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Бензодиазепиновый ингибитор бромодомена
EA023441B1 (ru) 2009-11-05 2016-06-30 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Бензодиазепиновый ингибитор бромодомена
US20130061612A1 (en) 2009-11-11 2013-03-14 E.I. Du Pont De Nemours And Company Refrigerant storage in secondary loop refrigeration systems
CA2812043A1 (en) 2010-04-23 2011-10-27 Kineta, Inc. Pyrimidinedione anti-viral compounds
CN103037865B (zh) 2010-05-14 2014-10-29 达那-法伯癌症研究所 用于治疗瘤形成、炎性疾病和其他失调的化合物
WO2011161031A1 (en) 2010-06-22 2011-12-29 Glaxosmithkline Llc Benzotriazolodiazepine compounds inhibitors of bromodomains
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
KR20140102276A (ko) 2011-12-07 2014-08-21 어펙티바,아이엔씨. 광고 효과의 감정 기반 평가
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US20130188311A1 (en) 2012-01-23 2013-07-25 International Business Machines Corporation Cooling and noise-reduction apparatus
CN104334526A (zh) 2012-04-20 2015-02-04 艾伯维公司 异吲哚酮衍生物
BR112014031068A2 (pt) 2012-06-12 2017-06-27 Abbvie Inc derivados piridinona e piridazinona
CN104620223B (zh) 2012-06-15 2018-11-16 英特尔公司 对于基于存储资历实现从不同线程进行转发的线程不可知的加载存储缓冲器
US20140094456A1 (en) 2012-10-02 2014-04-03 Intermune, Inc. Anti-fibrotic pyridinones
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
WO2014125408A2 (en) * 2013-02-12 2014-08-21 Aurigene Discovery Technologies Limited Substituted 1h-pyrrolopyridinone derivatives as kinase inhibitors
US9050346B2 (en) 2013-03-11 2015-06-09 Abbvie Inc. Bromodomain inhibitors
CN105189504B (zh) 2013-03-11 2017-07-18 艾伯维公司 稠合四环溴结构域抑制剂
SG11201507383WA (en) 2013-03-12 2015-10-29 Abbvie Inc Dihydro-pyrrolopyridinone bromodomain inhibitors
CN105164113B (zh) 2013-03-12 2018-03-02 艾伯维公司 吡咯酰胺抑制剂
PE20151788A1 (es) 2013-03-12 2015-12-20 Abbvie Inc Inhibidores de bromodominios tetraciclicos
US10131657B2 (en) 2013-06-28 2018-11-20 Abbvie Inc. Bromodomain inhibitors
AR096758A1 (es) 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
CN103387576A (zh) * 2013-08-09 2013-11-13 中国药科大学 基于嘌呤结构的芳酰胺类Raf激酶抑制剂及其制备方法和用途
CA2927567C (en) * 2013-10-18 2022-04-26 Celgene Quanticel Research, Inc. Bromodomain inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081280A1 (en) 2013-11-26 2015-06-04 Coferon, Inc. Bromodomain ligands capable of dimerizing in an aqueous solution
US20150148372A1 (en) 2013-11-26 2015-05-28 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
CA2932030A1 (en) 2013-12-09 2015-06-18 Abbvie Inc. Dihydropyridinone and dihydropyridazinone derivatives useful as bromodomain inhibitors
US9994581B2 (en) 2013-12-10 2018-06-12 Abbvie Inc. Bromodomain inhibitors
TWI735002B (zh) 2014-04-23 2021-08-01 美商英塞特公司 作為BET蛋白抑制劑之1H-吡咯并[2,3-c]吡啶-7(6H)-酮及吡唑并[3,4-c]吡啶-7(6H)-酮
MA40940A (fr) 2014-11-10 2017-09-19 Constellation Pharmaceuticals Inc Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
EP3294736B1 (en) 2015-05-11 2020-07-22 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
JP6606444B2 (ja) 2016-03-10 2019-11-13 株式会社Ｓｕｂａｒｕ 車両用制御装置
WO2017181177A1 (en) 2016-04-15 2017-10-19 Epizyme, Inc. Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors
BR112018071216A2 (pt) * 2016-04-15 2019-02-05 Abbvie Inc inibidores de bromodomínios
MX2018012664A (es) 2016-04-15 2019-03-07 Blueprint Medicines Corp Inhibidores de quinasa tipo receptor de activina.
MX2018012303A (es) 2016-04-15 2019-01-14 Syngenta Participations Ag Compuestos de piridazinona herbicida.
KR102467347B1 (ko) 2016-04-15 2022-11-14 바이엘 애니멀 헬스 게엠베하 피라졸로피리미딘 유도체
EP3468559B1 (en) 2016-06-09 2023-11-22 Dana Farber Cancer Institute, Inc. Methods of use and pharmaceutical combinations of hdac inhibitors with bet inhibitors
US20190134004A1 (en) 2016-06-16 2019-05-09 The University Of Chicago Methods and compositions for treating breast and prostate cancer
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
JP2019534262A (ja) 2016-10-14 2019-11-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
JP2019534264A (ja) 2016-10-14 2019-11-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
WO2018095933A1 (en) 2016-11-22 2018-05-31 Université D'aix-Marseille (Amu) Method of prognosticating, or for determining the efficiency of a compound for treating cancer
WO2018130174A1 (zh) 2017-01-11 2018-07-19 江苏豪森药业集团有限公司 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用
EP3609896A4 (en) 2017-04-14 2020-11-04 AbbVie Inc. BROMODOMAIN INHIBITORS
CN108976278B (zh) 2017-06-05 2021-04-06 海创药业股份有限公司 一种嵌合分子及其制备和应用
CN108690020A (zh) 2018-07-04 2018-10-23 清华大学 一种靶向降解bet蛋白的化合物及其应用

Also Published As

Publication number Publication date
EP3693369A3 (en) 2020-09-09
US10633379B2 (en) 2020-04-28
US20190345153A1 (en) 2019-11-14
EP3442972A4 (en) 2019-09-04
RU2741808C2 (ru) 2021-01-28
EP3693369A2 (en) 2020-08-12
DOP2018000227A (es) 2018-10-31
WO2017177955A1 (en) 2017-10-19
MA52814A (fr) 2022-04-27
IL261586B (en) 2021-05-31
AU2017251537B2 (en) 2020-10-08
JP6978424B2 (ja) 2021-12-08
CN109071534B (zh) 2021-11-23
AU2017251537A1 (en) 2018-09-13
RS60302B1 (sr) 2020-07-31
TW201738243A (zh) 2017-11-01
ME03759B (me) 2021-04-20
PH12018501920A1 (en) 2019-06-24
TW202304907A (zh) 2023-02-01
TWI704147B (zh) 2020-09-11
BR112018071216A2 (pt) 2019-02-05
SI3442972T1 (sl) 2020-07-31
AU2021200101A1 (en) 2021-03-18
ES2793239T3 (es) 2020-11-13
LT3442972T (lt) 2020-06-10
PL3442972T3 (pl) 2020-07-27
US20240360124A1 (en) 2024-10-31
CY1123025T1 (el) 2021-10-29
PT3442972T (pt) 2020-05-29
KR20180134350A (ko) 2018-12-18
SG11201808003RA (en) 2018-10-30
CA3018802A1 (en) 2017-10-19
CN109071534A (zh) 2018-12-21
UA124764C2 (uk) 2021-11-17
DK3442972T3 (da) 2020-04-27
MD3442972T2 (ro) 2020-08-31
MY190795A (en) 2022-05-12
JP2022024026A (ja) 2022-02-08
CO2018011064A2 (es) 2018-10-22
MA44674A (fr) 2019-02-20
ECSP18083519A (es) 2018-11-30
PH12018501920B1 (en) 2022-04-06
RU2018140061A (ru) 2020-05-15
RU2018140061A3 (es) 2020-08-20
HRP20200728T1 (hr) 2020-07-24
EP3442972B1 (en) 2020-03-04
AR108207A1 (es) 2018-07-25
CR20180541A (es) 2019-07-04
SMT202000312T1 (it) 2020-07-08
PE20190472A1 (es) 2019-04-04
CL2018002924A1 (es) 2018-12-21
JP2019511482A (ja) 2019-04-25
EP3442972A1 (en) 2019-02-20
MX2018012541A (es) 2019-01-17
HUE050217T2 (hu) 2020-11-30
MA44674B1 (fr) 2020-06-30
US20220017511A1 (en) 2022-01-20
IL261586A (en) 2018-10-31
US20200255426A1 (en) 2020-08-13
KR102250415B1 (ko) 2021-05-11
TWI764237B (zh) 2022-05-11
TW202122394A (zh) 2021-06-16

Similar Documents

Publication Publication Date Title
ECSP18083519A (es) Inhibidores de bromodominios
UY39630A (es) Inhibidores de bromodominios
CY1121413T1 (el) Διυδροπυρρολοπυριδινης αναστολεις ror-γαμμα
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
CR20160035A (es) Inhibidores de bromodominios
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
ECSP17026210A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2015011984A (es) Inhibidores de bromodominio de dihidro-pirrolopiridinona.
UY36285A (es) Compuestos que inhiben la proteína mcl-1
MX2015012431A (es) Pirrol amida como inhibidores.
CO2019009722A2 (es) Dendrímeros terapéuticos
CL2019001993A1 (es) Inhibidores selectivos de jak1.
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
CL2019000476A1 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CY1120602T1 (el) [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112019007591A2 (pt) inibidores de bromodomínios
BR112019007631A2 (pt) inibidores de bromodomínios
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20240122